In short
This article discusses a Phase 2 clinical trial investigating the effectiveness and safety of Plixorafenib (FORE8394), a drug designed to inhibit BRAF class 1 and class 2 alterations in cancer patients. The study focuses on patients with various types of tumors harboring BRAF alterations, including solid tumors and primary central nervous system (CNS) tumors. The trial aims to assess the drug's efficacy, safety, and other important factors in specific subgroups of patients.
At a glance
- Drug Name
- Plixorafenib (FORE8394)
- Trial Phase
- Phase 2
- Target Population
- Patients with tumors harboring BRAF alterations
- Age Range
- 10 years and older
- Primary Objectives
- Evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics
- Primary Endpoint
- Overall Response Rate (ORR)
- Secondary Endpoints
- Duration of Response, Progression-Free Survival, Disease Control Rate
- Tumor Types
- Solid tumors, primary CNS tumors, high-grade gliomas
- Administration
- Oral tablet
What is Plixorafenib?
Plixorafenib, also known as FORE8394 or PLX8394, is an investigational drug being developed to treat various types of cancer. It is a tablet taken by mouth that targets specific genetic changes in cancer cells.
How Does Plixorafenib Work?
Plixorafenib is designed to inhibit BRAF alterations, which are genetic changes that can drive cancer growth. Specifically, it targets both class 1 and class 2 BRAF alterations. By blocking these altered genes, plixorafenib aims to slow down or stop the growth of cancer cells.
What Conditions Does Plixorafenib Target?
Plixorafenib is being studied in patients with various types of cancer that have BRAF alterations, including:
- Solid tumors
- Primary central nervous system (CNS) tumors
- Gliomas (brain tumors), including:
- Glioblastoma
- Astrocytoma
- Oligodendroglioma
The drug is particularly focused on cancers with BRAF V600E mutations and BRAF fusions, which are specific types of genetic changes.
Clinical Trial Details
Plixorafenib is currently being studied in a Phase 2 clinical trial. This trial is designed to evaluate how well the drug works and how safe it is for patients. The study is divided into two main parts:
- Subprotocol A: Focuses on patients with solid tumors or primary CNS tumors that have BRAF fusions.
- Subprotocol B: Targets patients with recurrent high-grade gliomas (HGG) that have the BRAF V600E mutation.
Who is Eligible for the Trial?
The trial is open to both adults and children (10 years and older) who meet specific criteria. Key eligibility factors include:
- Having a confirmed BRAF alteration in their tumor
- Having cancer that has progressed or not responded to standard treatments
- Being in overall good health, apart from their cancer
Some patients may not be eligible if they have certain other medical conditions or have received specific prior treatments.
Potential Benefits of Plixorafenib
While the effectiveness of plixorafenib is still being studied, researchers hope it may offer several potential benefits:
- Shrinking tumors or slowing their growth
- Improving symptoms caused by the cancer
- Potentially offering a treatment option for patients who have limited choices
The trial will measure outcomes such as how many patients' tumors shrink (overall response rate) and how long the benefits last (duration of response).
Important Considerations
Patients considering participation in this trial should be aware of the following:
- As an investigational drug, the full risks and benefits of plixorafenib are not yet known.
- Participants will need to undergo regular tests and check-ups as part of the study.
- Some medications may interact with plixorafenib and need to be avoided during the trial.
- The trial involves a placebo-controlled design, meaning some participants may receive a placebo instead of the active drug.
It's crucial for patients to discuss all aspects of the trial with their healthcare team to determine if participation is right for them.